ENDOMETRIAL SEROUS ADENOCARCINOMA
Clinical trials for ENDOMETRIAL SEROUS ADENOCARCINOMA explained in plain language.
Never miss a new study
Get alerted when new ENDOMETRIAL SEROUS ADENOCARCINOMA trials appear
Sign up with your email to follow new studies for ENDOMETRIAL SEROUS ADENOCARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Experimental drug duo targets Hard-to-Treat cancers
Disease control OngoingThis early-phase trial tests a new targeted drug called MLN0128 combined with bevacizumab (Avastin) in about 50 patients whose glioblastoma or other solid tumors have returned or not responded to standard treatment. The main goal is to find the safest dose and see how the body ha…
Matched conditions: ENDOMETRIAL SEROUS ADENOCARCINOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 28, 2026 00:00 UTC
-
Targeted therapy boost for aggressive uterine cancer under study
Disease control TerminatedThis phase 3 trial tests whether adding targeted drugs (trastuzumab and pertuzumab) to standard chemotherapy can better shrink tumors in people with HER2-positive endometrial cancer. The study plans to enroll 360 participants with various stages of the disease. However, the trial…
Matched conditions: ENDOMETRIAL SEROUS ADENOCARCINOMA
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New drug cocktails show promise against tough endometrial cancer
Disease control OngoingThis study tests several drug combinations in women with endometrial cancer that has returned or not responded to treatment. The drugs work by blocking cancer cell growth or helping the immune system attack tumors. The goal is to see if these combinations can slow or stop the can…
Matched conditions: ENDOMETRIAL SEROUS ADENOCARCINOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Immunotherapy plus chemo shows promise for Tough-to-Treat endometrial cancer
Disease control OngoingThis phase III trial tests whether adding the immunotherapy drug pembrolizumab to standard chemotherapy (paclitaxel and carboplatin) helps people with advanced (stage III or IV) or recurrent endometrial cancer. About 800 participants received either the combo or chemo alone. The …
Matched conditions: ENDOMETRIAL SEROUS ADENOCARCINOMA
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New hope for advanced endometrial cancer: three-drug combos tested in major trial
Disease control OngoingThis study tested three different drug combinations in 349 people with advanced (stage III or IV) or recurrent endometrial cancer. The goal was to see which combination worked best at stopping the cancer from growing or spreading. Participants received either paclitaxel/carboplat…
Matched conditions: ENDOMETRIAL SEROUS ADENOCARCINOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New scan and dye combo may spot hidden cancer in lymph nodes
Diagnosis OngoingThis study looks at whether combining a special scan (PET/CT) with a dye that highlights lymph nodes can better detect cancer spread in women with high-risk endometrial cancer. About 100 women scheduled for surgery will get both tests before their operation. The goal is to see if…
Matched conditions: ENDOMETRIAL SEROUS ADENOCARCINOMA
Phase: NA • Sponsor: M.D. Anderson Cancer Center • Aim: Diagnosis
Last updated Jun 27, 2026 12:29 UTC
-
Experimental drug triapine tested in rare uterine cancer before surgery
Knowledge-focused OngoingThis early-phase trial is testing the drug triapine in 12 women with a rare and aggressive type of uterine cancer called uterine serous adenocarcinoma. Participants receive a single dose of triapine before their scheduled hysterectomy, and researchers analyze tissue samples to se…
Matched conditions: ENDOMETRIAL SEROUS ADENOCARCINOMA
Phase: EARLY_PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:06 UTC